SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

CADD522

Item No. 36679

CAS Registry No.: 199735-88-1
Formal Name: 3-[[(3,4-dichlorophenyl)amino]carbonyl]-bicyclo[2.2.1]hept-5-ene-2-carboxylic acid
MF: $C_{15}H_{13}Cl_2NO_3$
FW: 326.2
Purity: ≥98%
UV/Vis.: λ_{max}: 211, 255 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

CADD522 is supplied as a solid. A stock solution may be made by dissolving the CADD522 in the solvent of choice, which should be purged with an inert gas. CADD522 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of CADD522 in these solvents is approximately 3, 2, and 5 mg/ml, respectively.

Description

CADD522 is an inhibitor of RUNX family transcription factor 2 (RUNX2) binding to DNA.[1] It inhibits RUNX2 binding to osteoblast-specific element 2 (OSE2) oligonucleotides in a cell-free assay, as well as inhibits RUNX2 enrichment on matrix metalloproteinase-13 (MMP-13) promoters in MCF-7 cells when used at concentrations ranging from 100 to 1,000 nM. CADD522 (50 µM) decreases clonogenic survival in a panel of nine breast cancer cell lines. It decreases the expression of the RUNX2 target genes and metastasis markers *MMP-13* and *VEGF* in ectopic RUNX2-expressing T47D-RUNX2 and MCF-7-RUNX2 breast cancer cells. CADD522 (20 mg/kg, i.p.) reduces tumor volume and incidence in the MMTV-PyMT transgenic mouse model of breast cancer.

Reference

1. Kim, M.S., Gernapudi, R., Choi, E.Y., *et al.* Characterization of CADD522, a small molecule that inhibits RUNX2-DNA binding and exhibits antitumor activity. *Oncotarget.* **8(41)**, 70916-70940 (2017).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent *via* email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/21/2022

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM